Novo Holdings hot on diagnostics: This is the key to unlocking two of the largest healthcare issues

Investing in diagnostics is complicated, even for Novo Holdings – but due to the potential in the industry, the company is hungry for more acquisitions, after completing its largest-ever investment in a diagnostics company on Tuesday.

Novo Holdings Principal Investments Principal Sibel Arnes | Photo: Novo Holdings / PR

Through the acquisition of Welsh BBI group on Tuesday, Novo Holdings is demonstrating that the diagnostics area is an important field of interest for the Danish life science investor.

It has been seven years since Novo Holdings last took over majority ownership, and according to Christoffer Søderberg and Sibel Arnes from Novo Holdings' Principal Investments team, a lot is happening in this area, which makes it a highly interesting field for Novo Holdings.

Read the whole article

Get 14 days free access.
No credit card required.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Pfizer upgrades guidance for sales of covid-19 vaccine

The US pharmaceutical company Pfizer now predicts sales of its coronavirus vaccines will total USD 33.5bn this year. The previous estimate was UDS 26bn. Meanwhile, the company has revealed the guidance for its annual revenue.

Further reading

Related articles

Trial banner

Latest news

See all jobs